SDGR
NASDAQSchrodinger Inc.
Price$14.39+0.02 (+0.14%)
01:30 PM07:45 PM
News · 26 weeks43-62%
2025-12-142026-06-07
Mix1890d
- SEC Filings7(39%)
- Other6(33%)
- Insider3(17%)
- Earnings2(11%)
Latest news
25 items- SECSchrodinger Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Schrodinger, Inc. (0001490978) (Filer)
- PRSchrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)Schrödinger, Inc. (NASDAQ:SDGR) today reported that on May 18, 2026, the company granted (i) a non-statutory stock option to purchase 1,875 shares of the company's common stock to one newly hired employee and (ii) restricted stock units (RSUs) with respect to 18,766 shares of the company's common stock to seven newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, and were made as a material inducement to such employees' acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635
- SECSchrodinger Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure8-K - Schrodinger, Inc. (0001490978) (Filer)
- SECSEC Form 10-Q filed by Schrodinger Inc.10-Q - Schrodinger, Inc. (0001490978) (Filer)
- SECSchrodinger Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Schrodinger, Inc. (0001490978) (Filer)
- PRSchrödinger Reports First Quarter 2026 Financial ResultsFirst Quarter ACV of $28 Million, Representing 12% Growth Continued Momentum in Transition to Hosted Software Licensing Schrödinger to Launch Bunsen, an Agentic AI Co-Scientist, This Summer Lilly's Announced $2.3 Billion Acquisition of Ajax Validates Schrödinger's Track Record of High-Value Collaborations Schrödinger, Inc. (NASDAQ:SDGR) today announced financial results for the quarter ended March 31, 2026. "Our first quarter results show strong growth in both ACV and drug discovery revenue. ACV growth of 12 percent was driven by usage scale-ups and new deployments; we are also pleased with our progress transitioning customers to hosted licensing. The biopharmaceutical funding env
- PRSchrödinger to Participate in Upcoming Investor ConferencesSchrödinger, Inc. (NASDAQ:SDGR) today announced that management will participate in the following conferences in May: BofA Securities 2026 Healthcare Conference: Fireside chat on Wednesday, May 13, 2026, at 5:20 p.m. E.T. RBC 2026 Global Healthcare Conference: Fireside chat on Tuesday, May 19, 2026 at 2:05 p.m. E.T. The live discussions can be accessed in the "Investors" section of Schrödinger's website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming molecular discovery with its computational platform, which enables the discovery of novel, highly optimized molecules for drug development and materials design. Schröd
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Schrodinger Inc.SCHEDULE 13G/A - Schrodinger, Inc. (0001490978) (Subject)
- SECSEC Form DEFA14A filed by Schrodinger Inc.DEFA14A - Schrodinger, Inc. (0001490978) (Filer)
- SECSEC Form DEF 14A filed by Schrodinger Inc.DEF 14A - Schrodinger, Inc. (0001490978) (Filer)
- PRSchrödinger to Announce First Quarter 2026 Financial Results on May 5Schrödinger, Inc. (NASDAQ:SDGR) will report its first quarter 2026 financial results on Tuesday, May 5, 2026, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. The live webcast can be accessed in the "Investors" section of Schrödinger's website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming molecular discovery with its computational platform, which enables the discovery of novel, highly optimized molecules for drug development and materials design. Schrödinger's software platform is built on more than 30 years of R&D investment and is licensed by biotechnology, pharma
- INSIDERSEC Form 4 filed by Farid Ramy4 - Schrodinger, Inc. (0001490978) (Issuer)
- INSIDERSEC Form 4 filed by Jain Rachit4 - Schrodinger, Inc. (0001490978) (Issuer)
- PRSchrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)Schrödinger, Inc. (NASDAQ:SDGR) today reported that on April 16, 2026, the company granted restricted stock units (RSUs) with respect to 4,253 shares of the company's common stock to four newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, and were made as a material inducement to such employees' acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his or her employment compensation. The RSUs vest over four years, with 25 percent of such RSUs ve
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Schrodinger Inc.SCHEDULE 13G/A - Schrodinger, Inc. (0001490978) (Subject)
- INSIDERSEC Form 3 filed by new insider Abrams Therese Marie3 - Schrodinger, Inc. (0001490978) (Issuer)
- PRSchrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)Schrödinger, Inc. (NASDAQ:SDGR) today reported that on March 14, 2026, the company granted (i) a non-statutory stock option to purchase 1,950 shares of the company's common stock to one newly hired employee and (ii) restricted stock units (RSUs) with respect to 4,375 shares of the company's common stock to two newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, and were made as a material inducement to such employees' acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(
- SECSchrodinger Inc. filed SEC Form 8-K: Leadership Update8-K - Schrodinger, Inc. (0001490978) (Filer)
- INSIDERCAO Herman Jenny sold $17,764 worth of shares (1,383 units at $12.84), decreasing direct ownership by 4% to 34,804 units (SEC Form 4)4 - Schrodinger, Inc. (0001490978) (Issuer)
- INSIDEREVP & CFO Jain Rachit sold $21,033 worth of shares (1,631 units at $12.90), decreasing direct ownership by 3% to 52,596 units (SEC Form 4)4 - Schrodinger, Inc. (0001490978) (Issuer)
- INSIDEREVP, CLO & CPO Tran Yvonne sold $14,107 worth of shares (1,094 units at $12.89), decreasing direct ownership by 2% to 52,683 units (SEC Form 4)4 - Schrodinger, Inc. (0001490978) (Issuer)
- INSIDERPresident & CEO Farid Ramy sold $47,249 worth of shares (3,661 units at $12.91), decreasing direct ownership by 1% to 330,824 units (SEC Form 4)4 - Schrodinger, Inc. (0001490978) (Issuer)
- INSIDEROfficer Akinsanya Karen sold $17,625 worth of shares (1,366 units at $12.90), decreasing direct ownership by 2% to 69,956 units (SEC Form 4)4 - Schrodinger, Inc. (0001490978) (Issuer)
- INSIDEREVP, CTO & COO, Software Lorton Kenneth Patrick sold $15,761 worth of shares (1,222 units at $12.90), decreasing direct ownership by 1% to 89,241 units (SEC Form 4)4 - Schrodinger, Inc. (0001490978) (Issuer)
- INSIDEROfficer Abel Robert Lorne sold $16,653 worth of shares (1,300 units at $12.81), decreasing direct ownership by 2% to 55,897 units (SEC Form 4)4 - Schrodinger, Inc. (0001490978) (Issuer)
SDGR FAQ
7 questionsWhat does Schrodinger Inc. do?
Schrödinger, Inc. provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates through two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic...Where does SDGR stock trade?
Schrodinger Inc. (SDGR) is listed on NASDAQ.What sector and industry is SDGR in?
Schrodinger Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Schrodinger Inc. go public?
Schrodinger Inc. (SDGR) completed its IPO in 2020.What are analysts saying about SDGR?
Schrodinger Inc. has had 8 recent analyst actions on file. The most recent action was from BofA Securities: Buy with a $2400.00 price target on 2025-12-15. Recent price targets range from $1900.00 to $3800.00.What companies are similar to SDGR?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare SDGR side-by-side with any of them on Quantisnow.How can I track SDGR on Quantisnow?
Quantisnow aggregates Schrodinger Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SDGR to receive live email and push alerts on every new disclosure.